Pub Date : 2023-12-10DOI: 10.7704/kjhugr.2023.0042
Yuria Kim, J. Ahn, H. Jung, J. Noh, H. Na, Kee Wook Jung, Jeong Hoon Lee, D. Kim, K. Choi, H. Song, G. Lee
Objectives: The incidence of treatment failures following standard triple therapy (STT) for Helicobacter pylori eradication (HPE) has reached an unacceptable level. Sequential therapy (SQ) has emerged as a promising approach to counteract the escalation of antibiotic resistance. In this study, we used a chronological cohort dataset to conduct a comparative analysis of the eradication rates, compliance, and adverse events associated with the 7-day STT and SQ.Methods: A total of 789 patients underwent HPE treatment at Asan Medical Center between July 2013 and August 2017. Among them, 378 received a 7-day STT and 411 received a 10-day SQ. Baseline clinical data and treatment parameters were compared between the two treatment groups.Results: SQ demonstrated an eradication rate of 84.7% (348/411), which was superior to that of the 7-day STT (74.1%; p<0.001). The incidence of adverse events was also higher in the SQ group than in the STT group (17.5% vs. 11.1%; p=0.01). Nonetheless, treatment compliance was not significantly different between the groups (98.1% [SQ] vs. 96.8% [STT]; p=0.38). Among the patients undergoing second-line eradication, the SQ group displayed a lower eradication rate than the STT group (77.8% vs. 92.4%; p=0.028). Notably, the overall eradication rate did not differ significantly between the two groups (98.3% [STT] vs. 97.4% [SQ]; p=0.56).Conclusions: SQ exhibited superior efficacy compared with the 7-day STT as a first-line H. pylori treatment. Thus, SQ holds potential to serve as the replacement for the 7-day STT in treatment-naïve patients.
目的:标准三联疗法(STT)根除幽门螺杆菌(HPE)后治疗失败的发生率已达到不可接受的水平。序贯治疗(SQ)已成为对抗抗生素耐药性升级的一种有希望的方法。在这项研究中，我们使用时间顺序队列数据集对与7天STT和SQ相关的根除率、依从性和不良事件进行了比较分析。方法:2013年7月至2017年8月在峨山医疗中心接受HPE治疗的789例患者。其中378人接受了7天的STT, 411人接受了10天的SQ。比较两组患者的基线临床资料和治疗参数。结果:SQ的根除率为84.7%(348/411)，优于7 d STT的根除率(74.1%;p < 0.001)。SQ组的不良事件发生率也高于STT组(17.5% vs 11.1%;p = 0.01)。然而，治疗依从性在两组间无显著差异(98.1% [SQ] vs. 96.8% [STT];p = 0.38)。在接受二线根除的患者中，SQ组的根除率低于STT组(77.8% vs. 92.4%;p = 0.028)。值得注意的是，两组之间的总体根除率无显著差异(98.3% [STT] vs. 97.4% [SQ];p = 0.56)。结论:与7天STT相比，SQ作为幽门螺旋杆菌的一线治疗具有更好的疗效。因此，SQ有可能替代treatment-naïve患者的7天STT。
{"title":"Comparison of Helicobacter pylori Eradication Rates Using Standard Triple Therapy and Sequential Therapy","authors":"Yuria Kim, J. Ahn, H. Jung, J. Noh, H. Na, Kee Wook Jung, Jeong Hoon Lee, D. Kim, K. Choi, H. Song, G. Lee","doi":"10.7704/kjhugr.2023.0042","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0042","url":null,"abstract":"Objectives: The incidence of treatment failures following standard triple therapy (STT) for Helicobacter pylori eradication (HPE) has reached an unacceptable level. Sequential therapy (SQ) has emerged as a promising approach to counteract the escalation of antibiotic resistance. In this study, we used a chronological cohort dataset to conduct a comparative analysis of the eradication rates, compliance, and adverse events associated with the 7-day STT and SQ.Methods: A total of 789 patients underwent HPE treatment at Asan Medical Center between July 2013 and August 2017. Among them, 378 received a 7-day STT and 411 received a 10-day SQ. Baseline clinical data and treatment parameters were compared between the two treatment groups.Results: SQ demonstrated an eradication rate of 84.7% (348/411), which was superior to that of the 7-day STT (74.1%; p<0.001). The incidence of adverse events was also higher in the SQ group than in the STT group (17.5% vs. 11.1%; p=0.01). Nonetheless, treatment compliance was not significantly different between the groups (98.1% [SQ] vs. 96.8% [STT]; p=0.38). Among the patients undergoing second-line eradication, the SQ group displayed a lower eradication rate than the STT group (77.8% vs. 92.4%; p=0.028). Notably, the overall eradication rate did not differ significantly between the two groups (98.3% [STT] vs. 97.4% [SQ]; p=0.56).Conclusions: SQ exhibited superior efficacy compared with the 7-day STT as a first-line H. pylori treatment. Thus, SQ holds potential to serve as the replacement for the 7-day STT in treatment-naïve patients.","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-10DOI: 10.7704/kjhugr.2023.0062
Da Hyun Jung
{"title":"Does Types of 23S-Ribosomal RNA Point Mutations Affect Helicobacter pylori Eradication Rate in Clarithromycin-Based Triple Therapy?","authors":"Da Hyun Jung","doi":"10.7704/kjhugr.2023.0062","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0062","url":null,"abstract":"","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138585111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0030
Ah Cheon Park, Sung Eun Kim
{"title":"Precision Medicine for Gastric Cancer: Applicability from the Perspective of Helicobacter pylori Infection","authors":"Ah Cheon Park, Sung Eun Kim","doi":"10.7704/kjhugr.2023.0030","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0030","url":null,"abstract":"","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48139704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0033
Sun Hyung Kang
The Korean Journal of Helicobacter and Upper Gastrointestinal Research is an Open-Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. EDITORIAL ISSN 1738-3331 eISSN 2671-826X, https://doi.org/10.7704/kjhugr.2023.0033 Korean J Helicobacter Up Gastrointest Res, 2023;23(3):155-156
{"title":"Possibility of Endoscopic Resection in Localized Gastric Mucosa-associated Lymphoid Tissue Lymphoma","authors":"Sun Hyung Kang","doi":"10.7704/kjhugr.2023.0033","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0033","url":null,"abstract":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research is an Open-Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. EDITORIAL ISSN 1738-3331 eISSN 2671-826X, https://doi.org/10.7704/kjhugr.2023.0033 Korean J Helicobacter Up Gastrointest Res, 2023;23(3):155-156","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48186859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0031
Oong Hee Shin, J. Kim, B. Kim
A 51-year-old man with a 10-day history of acute-onset dysphagia presented with inability to swallow anything orally. The patient was unable to swallow any radiopaque contrast medium; therefore, a videofluoroscopic swallow study could not be performed. Brain imaging, neurological findings, and initial endoscopy findings were normal. Neck computed tomography suggested left vocal cord paralysis. The patient was diagnosed with diabetes one year prior to presentation but did not receive any treatment. Insulin therapy during hospitalization controlled the patient’s blood glucose levels, and his symptoms improved without any sequelae. We present a rare case of vocal cord paralysis secondary to controlled diabetes. The initial endoscopic examination did not include thorough evaluation of the vocal cords; therefore, accurate diagnosis was challenging in this case.
{"title":"Dysphagia Secondary to Vocal Cord Paralysis: A Case Report","authors":"Oong Hee Shin, J. Kim, B. Kim","doi":"10.7704/kjhugr.2023.0031","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0031","url":null,"abstract":"A 51-year-old man with a 10-day history of acute-onset dysphagia presented with inability to swallow anything orally. The patient was unable to swallow any radiopaque contrast medium; therefore, a videofluoroscopic swallow study could not be performed. Brain imaging, neurological findings, and initial endoscopy findings were normal. Neck computed tomography suggested left vocal cord paralysis. The patient was diagnosed with diabetes one year prior to presentation but did not receive any treatment. Insulin therapy during hospitalization controlled the patient’s blood glucose levels, and his symptoms improved without any sequelae. We present a rare case of vocal cord paralysis secondary to controlled diabetes. The initial endoscopic examination did not include thorough evaluation of the vocal cords; therefore, accurate diagnosis was challenging in this case.","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47619183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0035
Seung Joo Kang
The Korean Journal of Helicobacter and Upper Gastrointestinal Research is an Open-Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. IMAGE OF THE ISSUE ISSN 1738-3331 eISSN 2671-826X, https://doi.org/10.7704/kjhugr.2023.0035 Korean J Helicobacter Up Gastrointest Res, 2023;23(3):225-227
{"title":"Gastric Cancer of the Cardia Detected on Screening Endoscopy","authors":"Seung Joo Kang","doi":"10.7704/kjhugr.2023.0035","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0035","url":null,"abstract":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research is an Open-Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. IMAGE OF THE ISSUE ISSN 1738-3331 eISSN 2671-826X, https://doi.org/10.7704/kjhugr.2023.0035 Korean J Helicobacter Up Gastrointest Res, 2023;23(3):225-227","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47925649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0034
Jong Kyu Park
A variety of proton pump inhibitors (PPIs) have been developed in Korea since the introduction of omeprazole (the first PPI) in 1989. PPIs have served as the basic therapeutic approach for the management of gastric acid-related diseases for 30 years and remain among the most widely used drugs. Recently, potassium-competitive acid blockers (PCABs) have been developed both in Korea and abroad, demonstrating superior or non-inferior effects compared to existing PPIs in treating gastroesophageal reflux disease or Helicobacter pylori eradication, among others. Indications vary based on the various types and dosages of PPIs and PCABs, and several factors, including patients’ underlying disease, safety profile, particularly with regard to drug-drug interactions, and types of formulations of PPIs and PCABs need to be considered prior to prescribing these medications. In this article, we discuss the criteria for reimbursement of various PPIs and PCABs in Korea, along with considerations for prescribing these drugs based on patients’ underlying diseases.
{"title":"Optimal Use of Proton Pump Inhibitors and Potassium-competitive Acid Blockers","authors":"Jong Kyu Park","doi":"10.7704/kjhugr.2023.0034","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0034","url":null,"abstract":"A variety of proton pump inhibitors (PPIs) have been developed in Korea since the introduction of omeprazole (the first PPI) in 1989. PPIs have served as the basic therapeutic approach for the management of gastric acid-related diseases for 30 years and remain among the most widely used drugs. Recently, potassium-competitive acid blockers (PCABs) have been developed both in Korea and abroad, demonstrating superior or non-inferior effects compared to existing PPIs in treating gastroesophageal reflux disease or Helicobacter pylori eradication, among others. Indications vary based on the various types and dosages of PPIs and PCABs, and several factors, including patients’ underlying disease, safety profile, particularly with regard to drug-drug interactions, and types of formulations of PPIs and PCABs need to be considered prior to prescribing these medications. In this article, we discuss the criteria for reimbursement of various PPIs and PCABs in Korea, along with considerations for prescribing these drugs based on patients’ underlying diseases.","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41965230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0044
Y. Choe
The Korean Journal of Helicobacter and Upper Gastrointestinal Research is an Open-Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. BRIEF REPORT ISSN 1738-3331 eISSN 2671-826X, https://doi.org/10.7704/kjhugr.2023.0044 Korean J Helicobacter Up Gastrointest Res, 2023;23(3):218-221
{"title":"Antibiotic Resistance and Helicobacter pylori Eradication Therapy","authors":"Y. Choe","doi":"10.7704/kjhugr.2023.0044","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0044","url":null,"abstract":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research is an Open-Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. BRIEF REPORT ISSN 1738-3331 eISSN 2671-826X, https://doi.org/10.7704/kjhugr.2023.0044 Korean J Helicobacter Up Gastrointest Res, 2023;23(3):218-221","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49321440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0022
J. Noh, Kee Don Choi
Article: Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial (Gastroenterology 2022;163:608-619
{"title":"Vonoprazan-based Dual and Triple Therapy for Helicobacter pylori Eradication","authors":"J. Noh, Kee Don Choi","doi":"10.7704/kjhugr.2023.0022","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0022","url":null,"abstract":"Article: Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial (Gastroenterology 2022;163:608-619","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46521535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15DOI: 10.7704/kjhugr.2023.0043
Mun Young Cho, Y. Cho
Owing to their superior pharmacokinetic and pharmacodynamic profiles, potassium-competitive acid blockers (P-CABs) score over proton pump inhibitors (PPIs) in the treatment of gastric acid-related disorders and may provide clinical benefit in the management of these conditions. Previous studies have compared P-CABs with PPIs for treatment of gastric acid-related disorders, and current data show that P-CABs are non-inferior to PPIs in the treatment of erosive esophagitis and as maintenance therapy. P-CABs are useful for effective healing and as maintenance medications in patients with severe esophagitis. These drugs also aid with healing of peptic ulcers and artificial ulcers secondary to gastric endoscopic submucosal dissection (ESD). Few studies have discussed prevention of delayed ulcer bleeding after gastric ESD and ulcers associated with long-term nonsteroidal anti-inflammatory drug administration. Well-controlled, large-scale prospective studies are warranted in future to compare P-CABs with PPIs.
{"title":"Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders","authors":"Mun Young Cho, Y. Cho","doi":"10.7704/kjhugr.2023.0043","DOIUrl":"https://doi.org/10.7704/kjhugr.2023.0043","url":null,"abstract":"Owing to their superior pharmacokinetic and pharmacodynamic profiles, potassium-competitive acid blockers (P-CABs) score over proton pump inhibitors (PPIs) in the treatment of gastric acid-related disorders and may provide clinical benefit in the management of these conditions. Previous studies have compared P-CABs with PPIs for treatment of gastric acid-related disorders, and current data show that P-CABs are non-inferior to PPIs in the treatment of erosive esophagitis and as maintenance therapy. P-CABs are useful for effective healing and as maintenance medications in patients with severe esophagitis. These drugs also aid with healing of peptic ulcers and artificial ulcers secondary to gastric endoscopic submucosal dissection (ESD). Few studies have discussed prevention of delayed ulcer bleeding after gastric ESD and ulcers associated with long-term nonsteroidal anti-inflammatory drug administration. Well-controlled, large-scale prospective studies are warranted in future to compare P-CABs with PPIs.","PeriodicalId":22895,"journal":{"name":"The Korean Journal of Helicobacter and Upper Gastrointestinal Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44295023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：